All In Biotech

Drug Trial Radar · NCT00095758

A Study of Adjunctive Aripiprazole in Participants With Major Depressive Disorder

A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,151 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,151

Actual

Start

Sep 1, 2004

Primary completion

Dec 1, 2006

Study completion Dec 1, 2006

Sponsor

Sponsor type
Industry
Collaborators
Otsuka America Pharmaceutical
First posted
Nov 9, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive Disorder.

Conditions

  • Major Depressive Disorder

Interventions

  • Antidepressant + PlaceboDrug

    Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.

  • Antidepressant + AripiprazoleDrug

    Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in a depression rating scale at endpointTime frame: Baseline, Week 8

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution

    Beverly Hills, California

  • Local Institution

    Burbank, California

  • Local Institution

    National City, California

  • Local Institution

    Orange, California

  • Local Institution

    Pasadena, California

  • Local Institution

    Denver, Colorado

  • Local Institution

    Farmington, Connecticut

  • Local Institution

    Jacksonville, Florida

  • Local Institution

    Orlando, Florida

  • Local Institution

    Atlanta, Georgia

  • Local Institution

    Rockville, Maryland

  • Local Institution

    Albuquerque, New Mexico

  • Local Institution

    Brooklyn, New York

  • Local Institution

    New York, New York

  • Local Institution

    Cincinnati, Ohio

  • Local Institution

    Toledo, Ohio

  • Local Institution

    Portland, Oregon

  • Local Institution

    Pittsburgh, Pennsylvania

  • Local Institution

    Memphis, Tennessee

  • Local Institution

    Dallas, Texas

  • Local Institution

    Houston, Texas

  • Local Institution

    Arlington, Virginia

  • Local Institution

    Herndon, Virginia

  • Local Institution

    Richmond, Virginia

  • Local Institution

    Bellevue, Washington

  • Local Institution

    Seattle, Washington

  • Local Institution

    Brown Deer, Wisconsin

  • Local Institution

    Middleton, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.